11月17日 - ** 制药商Tonix Pharmaceuticals TNXP.O股价盘前上涨16.2%至18.43美元
** 该公司表示，其新药Tonmya是15年多来首个获批的纤维肌痛治疗药物，目前可在全美药店凭处方购买。
** 纤维肌痛是一种慢性疾病，会引起广泛的疼痛和疲劳
** Co公司的Tonmya每天睡前服用一次，旨在缓解约1000万美国人（其中大部分是女性）的慢性疼痛 - TNXP
** 该公司称，两项后期试验显示，与安慰剂相比，该药在 14 周后疼痛明显减轻，因此获得批准。
** 截至上次收盘，该公司股价年累计下跌约 52
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.